Evaluation of breast and gynecologic cancers by positron emission tomography (Q34755362)

4 August 2017

1 reference

title

Evaluation of breast and gynecologic cancers by positron emission tomography (English)

1 reference

4 August 2017

Farrokh Dehdashti

1

1 reference

4 August 2017

Barry A Siegel

series ordinal

2

1 reference

4 August 2017

publication date

1 April 2002

1 reference

Seminars in Roentgenology

4 August 2017

published in

1 reference

4 August 2017

volume

37

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

151-168

1 reference

describes a project that uses

4 August 2017

positron emission tomography

1 reference

inferred from title

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Role and evaluation of mammography and other imaging methods for breast cancer detection, diagnosis, and staging

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Effect of patients' being prone during FDG PET for the diagnosis of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Breast masses: mammographic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

1 reference

7 January 2021

Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

The Application of Positron Emission Tomographie Imaging With Fluorodeoxyglucose to the Evaluation of Breast Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Diagnostic value of positron emission tomography for detecting breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positron emission tomography in breast cancer: a clinicopathological correlation of results

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

The Potential of F-18-FDG PET in Breast Cancer. Detection of Primary Lesions, Axillary Lymph Node Metastases, or Distant Metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positron emission mammographic instrument: initial results.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Technique to obtain positron emission mammography images in registration with x-ray mammograms.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

F-18 FDG uptake in breast infection and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Mammographic features of "early" breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

The predictive value of certain mammographic signs in screening for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

MR imaging of the breast for the detection, diagnosis, and staging of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Association between [ 18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Whole body skeletal imaging with [18F]fluoride ion and PET

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

[18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Breast cancer: PET imaging of estrogen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Metabolic flare: indicator of hormone responsiveness in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Detection of pelvic lymph node metastases in gynecologic malignancy: a comparison of CT, MR imaging, and positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: Potential impact on treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

FDG-PET Evaluation of Carcinoma of the Cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix: a retrospective review

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Lymph node staging by positron emission tomography in patients with carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Radiology in the management of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG)

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Clinical Impact of 18F-FDG-PET in the Suspicion of Recurrent Ovarian Carcinoma Based on Elevated Tumor Marker Serum Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Clinical value of positron emission tomography with FDG for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Experience with positron emission tomography (PET) scans in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: preliminary findings on positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-198X%2802%2980034-7

7 January 2021

10.1016/S0037-198X(02)80034-7

Identifiers

DOI

1 reference

4 August 2017

1 reference